Publications (287) View all
-
Article: Brain metastatic volume and white matter lesions in advanced cancer patients.
[show abstract] [hide abstract]
ABSTRACT: Brain white matter T2 hyperintensities (WMH) are a frequent MRI finding in adults, both in asymptomatic and in cancer patients. The aim of our study is to determine the relationship between quantitative measures of the volume of WMH and the volume of brain metastatic lesions at the first MRI diagnosis of brain metastases in a population of advanced cancer patients. Brain MRI examinations of 162 consecutive patients were included and 984 brain metastases at first diagnosis were studied. Axial FLAIR images were used to visualize peri-lesional edema and to segment WMH; multiplanar contrast-enhanced T1-weighted TSE images were used to detect, count, segment and measure metastatic lesions. Segmentation of WMH on FLAIR images was performed after linear image registration to eliminate peri-lesional edema from the WMH masks. The distribution of the volumes of metastatic lesions was significantly different (ANOVA, p = 0.003) among all patients and among lung cancer patients (ANOVA, p = 0.003), with higher volumes of metastatic lesions in a higher proportion of patients when WMH were absent. There were no significant differences among groups at the 10 cc threshold of WMH. We found that volumes of brain metastases at the first MR diagnosis in a sample of advanced cancer patients and in the group of lung cancer patients were significantly lower if WMH were present; we suggest that WMH may represent a clinical MRI bio-marker of brain micro-environment resistance to the occurrence of brain metastases.Journal of Neuro-Oncology 05/2013; · 3.21 Impact Factor -
Article: Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: To test the hypothesis that the oral cavity is a potential source for implantable pacemaker and cardioverter defibrillators infections, the bacterial diversity on explanted rhythm heart management devices was investigated and compared to the oral microbiome. METHODS: A metagenomic approach was used to analyze the bacterial diversity on the surfaces of non-infected and infected pacemakers. The DNA from surfaces swaps of 24 non-infected and 23 infected pacemaker were isolated and subjected to bacterial-specific DNA amplification, single strand conformation polymorphism- (SSCP) and sequencing analysis. Species-specific primer sets were used to analyze for any correlation between bacterial diversity on pacemakers and in the oral cavity. RESULTS: DNA of bacterial origin was detected in 21 cases on infected pacemakers and assigned to the bacterial phylotypes Staphylococcus epidermidis, Propionibacterium acnes, Staphylococcus aureus, Staphylococcus schleiferi and Stapyhlococcus sp.. In 17 cases bacterial DNA was found on pacemakers with no clinical signs of infections. On the basis of the obtained sequence data, the phylotypes Propionibacterium acnes, Staphylococcus sp. and an uncultured bacterium were identified. Propionibacterium acnes and Staphylococcus epidermidis were the only bacteria detected in pacemeaker (n = 25) and oral samples (n = 11). CONCLUSIONS: The frequency of the coincidental detection of bacteria on infected devices and in the oral cavity is low and the detected bacteria are highly abundant colonizers of non-oral human niches.The transmission of oral bacteria to the lead or device of implantable pacemaker or cardioverter defibrillators is unlikely relevant for the pathogenesis of pacemaker or cardioverter defibrillators infections.Clinical sarcoma research. 04/2013; 3(1):6. -
Article: 'Old' and 'new' drugs for the treatment of cancer pain.
[show abstract] [hide abstract]
ABSTRACT: Introduction: More than 20 years ago the World Health Organization (WHO) published the booklet 'Cancer Pain Relief', including the fundamentals and clear principles, which was summarized in five simple sentences: 'by mouth', 'by the clock', 'by the ladder', 'for the individual' and 'attention to detail'. Over the years, several modifications to the analgesic ladder have been proposed, as the addition of two further steps, related to the switch of opioid and/or non-invasive route of administration, and to the use of invasive approaches, or again the skip of the second step; nevertheless the educational value and benefits related to the worldwide dissemination are of paramount importance. Areas covered: To date, all the guidelines are inspired by the strategy of WHO; below some of the most important international guidelines published in the last two years are compared, particularly as regards the criteria of choice of opioids for moderate/severe pain. Expert opinion: The discussion on the role of the second step of the WHO analgesic ladder is still open. The challenge for new formulations of 'old' opioids will be to better manage cancer pain, with more tailored efficacy and possibly less side effects.Expert Opinion on Pharmacotherapy 03/2013; 14(4):425-33. · 3.20 Impact Factor -
Article: Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
[show abstract] [hide abstract]
ABSTRACT: Until the recent approval of vinflunine, no standard second-line chemotherapy existed for advanced transitional cell carcinoma (TCC). Few data exist about third-line chemotherapy for metastatic disease. Although administered in up-front regimens, anthracyclines were never evaluated beyond second-line treatment. This study assessed the activity of pegylated liposomal doxorubicin (PLD) in patients with advanced TCC previously treated with two chemotherapy regimens. From May 2005 to June 2009, 23 patients with metastatic TCC were recruited: median age was 62 years (49-76 years) with a median ECOG PS of 1. Patients received PLD 35 mg/m(2) every 21 days. All patients were evaluable for efficacy and toxicity. No patient showed complete response. Three patients (13 %) had partial response; seven patients (30 %) showed stable disease for a disease control rate of 43 %. The median time to progression (TTP) was 4.1 months with a median survival time (MST) of 6.3 months. Treatment was well tolerated: no patient developed grade 4 toxicities. This is the first study which evaluated the role of anthracyclines as third-line chemotherapy in metastatic TCC. Despite its manageable profile of toxicity, PLD showed modest activity. Beyond second-line chemotherapy, supportive care still represents the best therapeutic option for patients with metastatic TCC.Medical Oncology 03/2013; 30(1):407. · 2.14 Impact Factor -
Article: Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens.
Expert opinion on therapeutic targets 02/2013; · 3.72 Impact Factor
